GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 25, 2016

Primary Completion Date

August 6, 2019

Study Completion Date

August 6, 2019

Conditions
Solid Organ Cancers
Interventions
BIOLOGICAL

GL-ONC1

"Dose and Regimen:~1. Single dose group: Cohort 1 dose is 1 × 109 pfu~2. Multiple dose groups:~ * Cohort 2 dose is 1 × 109 pfu × 5 consecutive days~ * Cohorts 3 and 4 dose is 2 × 109 pfu × 5 consecutive days~ * Cohorts 5 and 6 dose escalates at 2,3,5,5,5 × 109 pfu.~Route: GL-ONC1 is delivered as a bolus IV injection."

Trial Locations (1)

92093

UC San Diego Moores Cancer Center, La Jolla

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genelux Corporation

INDUSTRY

lead

Andrew Lowy

OTHER